Table of contents


Top

Editorials

The other path for follow-ons p715

doi:10.1038/nbt0708-715

With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.


In need of counseling? p716

doi:10.1038/nbt0708-716

Moves to clamp down on companies offering direct-to-consumer genetic tests are out of step with personal genomics and its potential to empower individuals' role in their own healthcare.


Top

News

euro2 billion IMI launched with European pharma pp717 - 718

John Hodgson

doi:10.1038/nbt0708-717


Dyax backs albumin p718

Mark Ratner

doi:10.1038/nbt0708-718


Commercial interest waxes for IGF-1 blockers pp719 - 720

Randy Osborne

doi:10.1038/nbt0708-719


Meta-analysis torpedoes blood substitutes pp721 - 723

Charlie Schmidt

doi:10.1038/nbt0708-721a


UK passes hybrids p721

Nuala Moran

doi:10.1038/nbt0708-721b


Tighter gene tests p721

Jeff Fox

doi:10.1038/nbt0708-721c


Biofuels, take two p722

Emily Waltz

doi:10.1038/nbt0708-722a


50 cancers to be sequenced p722

Henry Nicholls

doi:10.1038/nbt0708-722b


Pfizer jettisons Esperion pp724 - 725

Catherine Shaffer

doi:10.1038/nbt0708-724


Genetically modified mosquitoes p725

Susan Aldridge

doi:10.1038/nbt0708-725a


Pan-EU Biobanks p725

Barbara Nasto

doi:10.1038/nbt0708-725b


Profile: Julian Davies p727

George S. Mack

doi:10.1038/nbt0708-727

An icon of the European biotech industry and a pioneer of metagenomics, Julian Davies continues to pursue his lifelong love affair with microbiology.


Data Page

State of the biotech sector—2007 p728

Stacy Lawrence

doi:10.1038/nbt0708-728


News Feature

Poised to branch out pp729 - 732

Vivien Marx

doi:10.1038/nbt0708-729

Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.


Top

Bioentrepreneur

Building a business

Preparing for (and avoiding) the courtroom pp733 - 735

Jeff Wolfson & Russ Emerson

doi:10.1038/bioe.2008.6


Top

Opinion and Comment

Correspondence

Europe to ban direct-to-consumer genetic tests? pp736 - 737

Pascal Borry

doi:10.1038/nbt0708-736


Dichotomies between computational and mathematical models pp737 - 738

C Anthony Hunt, Glen E P Ropella, Sunwoo Park & Jesse Engelberg

doi:10.1038/nbt0708-737


Reply to Dichotomies between computational and mathematical models pp738 - 739

doi:10.1038/nbt0708-738


HLA-haplotype banking and iPS cells pp739 - 740

Norio Nakatsuji, Fumiaki Nakajima & Katsushi Tokunaga

doi:10.1038/nbt0708-739


Global mRNA changes in microarray experiments pp741 - 742

Matthew A Hannah, Henning Redestig, Andrea Leisse & Lothar Willmitzer

doi:10.1038/nbt0708-741


Commentary

(Re)defining biopharmaceutical pp743 - 751

Ronald A Rader

doi:10.1038/nbt0708-743

Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.


Top

Features

Public biotech 2007—the numbers pp753 - 762

Stacy Lawrence & Riku Lähteenmäki

doi:10.1038/nbt0708-753

Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.


Patents

How many patents does a biopharmaceutical company need? pp763 - 766

Deepak Kumar Parida, Ritu Mehdiratta & Gayatri Saberwal

doi:10.1038/nbt0708-763

Young biotech companies may not need extensive patent portfolios to survive or grow.


Recent patent applications in mass spectrometry p767

doi:10.1038/nbt0708-767


Top

News and Views

Hitting the mother lode of tumor angiogenesis pp769 - 770

Daylon James, Sina Rabbany & Shahin Rafii

doi:10.1038/nbt0708-769

An oral formulation of an antiangiogenic drug may allow long-term anti-cancer therapy.

See also: Research by Benny et al.


Setting the standard in synthetic biology pp771 - 774

Adam Arkin

doi:10.1038/nbt0708-771

Standards for characterization, manufacture and sharing of information about modular biological devices may lead to a more efficient, predictable and design-driven genetic engineering science.

See also: Research by Canton et al.


The long and short of carbon nanotube toxicity pp774 - 776

Kostas Kostarelos

doi:10.1038/nbt0708-774

Toxicological and pharmacological studies suggest guidelines for the safe use of carbon nanotubes in medicine.


Research Highlights p777

doi:10.1038/nbt0708-777


Top

Research

Analysis

A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis pp779 - 785

Thomas A Down, Vardhman K Rakyan, Daniel J Turner, Paul Flicek, Heng Li, Eugene Kulesha, Stefan Gräf, Nathan Johnson, Javier Herrero, Eleni M Tomazou, Natalie P Thorne, Liselotte Bäckdahl, Marlis Herberth, Kevin L Howe, David K Jackson, Marcos M Miretti, John C Marioni, Ewan Birney, Tim J P Hubbard, Richard Durbin, Simon Tavaré & Stephan Beck

doi:10.1038/nbt1414

An inability to estimate absolute DNA methylation levels has slowed progress in understanding the role of this epigenetic modification in health and disease. Down et al. describe an algorithm for analyzing methylated DNA immunoprecipitation profiles generated using either high-throughput sequencing or oligonucleotide arrays.


Perspective

Refinement and standardization of synthetic biological parts and devices pp787 - 793

Barry Canton, Anna Labno & Drew Endy

doi:10.1038/nbt1413

See also: News and Views by Arkin


Brief Communications

Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds pp795 - 797

Danwei Huangfu, René Maehr, Wenjun Guo, Astrid Eijkelenboom, Melinda Snitow, Alice E Chen & Douglas A Melton

doi:10.1038/nbt1418

Existing methods for reprogramming somatic cells to 'induced pluripotent stem cells' are inefficient, with only a small fraction of the starting cell population becoming pluripotent. Working with mouse embryonic fibroblasts, Hunagfu et al. increase reprogramming efficiency by treatment with DNA methyltransferase and histone deacetylase inhibitors.


Articles

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity pp799 - 807

Ofra Benny, Ofer Fainaru, Avner Adini, Flavia Cassiola, Lauren Bazinet, Irit Adini, Elke Pravda, Yaakov Nahmias, Samir Koirala, Gabriel Corfas, Robert J D'Amato & Judah Folkman

doi:10.1038/nbt1415

Widespread use of antiangiogenic drugs for cancer therapy is limited in part by the requirement for intravenous injection. Benny et al. describe an oral formulation of an antiangiogenic small molecule that inhibits tumor growth and prevents liver metastases in mice.

See also: News and Views by James et al.


Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases pp808 - 816

Elena E Perez, Jianbin Wang, Jeffrey C Miller, Yann Jouvenot, Kenneth A Kim, Olga Liu, Nathaniel Wang, Gary Lee, Victor V Bartsevich, Ya-Li Lee, Dmitry Y Guschin, Igor Rupniewski, Adam J Waite, Carmine Carpenito, Richard G Carroll, Jordan S Orange, Fyodor D Urnov, Edward J Rebar, Dale Ando, Philip D Gregory, James L Riley, Michael C Holmes & Carl H June

doi:10.1038/nbt1410


Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 pp817 - 823

Yukihiko Aikawa, Kimiko Morimoto, Tetsuya Yamamoto, Hisaaki Chaki, Akira Hashiramoto, Hirokazu Narita, Shuichi Hirono & Shunichi Shiozawa

doi:10.1038/nbt1412

Therapies that target only one inflammatory cytokine such as tumor necrosis factor alpha are often insufficient to treat rheumatoid arthritis. Aikawa et al. show that a small molecule targeting c-Fos/AP-1, a transcription factor that regulates both inflammatory cytokines and matrix metalloproteinases, inhibits type II collagen-induced arthritis in mice.


Letter

Electrostatic readout of DNA microarrays with charged microspheres pp825 - 830

Nathan G Clack, Khalid Salaita & Jay T Groves

doi:10.1038/nbt1416

Microarray platforms usually rely on fluorescence detection. Clack et al. present an equally sensitive, label-free technique that electrostatically detects DNA or RNA hybridization after randomly dispersing charged microspheres onto the microarray surface.


Top

Corrigenda

Corrigendum: Large-scale chemical dissection of mitochondrial function p831

Bridget K Wagner, Toshimori Kitami, Tamara J Gilbert, David Peck, Arvind Ramanathan, Stuart L Schreiber, Todd R Golub & Vamsi K Mootha

doi:10.1038/nbt0708-831a


Corrigendum: Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells p831

Gabsang Lee, Hyesoo Kim, Yechiel Elkabetz, George Al Shamy, Georgia Panagiotakos, Tiziano Barberi, Viviane Tabar & Lorenz Studer

doi:10.1038/nbt0708-831b


Top

Errata

Erratum: Looking forward, looking back p831

doi:10.1038/nbt0708-831c


Erratum: Is personalized medicine finally arriving? p831

Malorye Allison

doi:10.1038/nbt0708-831d


Top

Naturejobs

Careers and Recruitment

A walk through the Valley of Death pp833 - 834

Mari Paul

doi:10.1038/nbt0708-833

Expert tips for acquirers and acquirees to get through a difficult post-merger integration.


People

People p836

doi:10.1038/nbt0708-836


Top